Interviews with Key Healthcare Opinion Leaders - Episode #103 cover art

Interviews with Key Healthcare Opinion Leaders - Episode #103

Interviews with Key Healthcare Opinion Leaders - Episode #103

Listen for free

View show details

About this listen

 Dr. Andrew Hertler, Senior Advisor / Chief Medical Officer – emeritus for Evolent, explains ODAC’s September 2024 vote to support the FDA’s decision to restrict the use of PD-1 inhibitor drugs such as Opdivo, Keytruda, and Tevimbra for PD-L1-negative stomach cancer and esophageal cancer, and his support of using biomarkers to predict outcomes.

Hosted on Acast. See acast.com/privacy for more information.
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.